Phyllis Whiteley

Phyllis Whiteley, PhD, is a Venture Partner at Playground Global with an extensive background in life sciences, venture capital, and entrepreneurship.1 Her career is focused on personalized medicine, global healthcare, and transformative life science innovations.1

Professional Experience

Dr. Whiteley's career spans various sectors:

Venture Capital and Consulting:

• Currently serves as a Venture Partner at Playground Global2
• Consultant to entrepreneurs and start-ups in life sciences1
• Previously held positions at Mohr Davidow Ventures and 5AM Ventures1

Executive Roles:

• CEO and founder of Didimi (2011-2013)1
• Interim CEO of Verinata Health (acquired by Illumina)1
• Officer and Senior VP of Business Development and Licensing at Perlegen Sciences1

Pharmaceutical Industry:

• Vice President at Roche (1994-2004), with roles in research, business development, and portfolio management1
• Senior Research Immunologist at Merck1

Expertise and Contributions

Dr. Whiteley's expertise includes:

• Strategic planning and financing
• Partnerships and mergers & acquisitions
• Building executive teams
• Portfolio management

She has contributed to multiple new chemical entities and publications in pharmacology, immunology, and inflammation.1

Board Positions

Dr. Whiteley currently serves on the boards of:

• Bodyport (Chair)
• NalluBio (Chair and co-founder)1

She has previously served on numerous other boards, including RainDance Technologies, Verinata, and the Personalized Medicine Coalition.1

Education

• PhD in Pharmacology from Washington University in St. Louis
• BA in Chemistry from Washington University in St. Louis1

Dr. Whiteley's diverse experience and expertise make her a valuable asset in the life sciences and venture capital sectors, particularly in areas of innovation and emerging technologies.